Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy
Patrizia Ciammella(Azienda Sanitaria Unità Locale di Reggio Emilia), Francesco Merli(Azienda Sanitaria Unità Locale di Reggio Emilia), Michela Buglione(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Andrea Riccardo Filippi(University of Turin), Gabriele Simontacchi(Azienda Ospedaliero-Universitaria Careggi), Carlo Furlan(Centro di Riferimento Oncologico), Umberto Ricardi(Azienda Ospedaliero Universitaria San Giovanni Battista), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Michele Spina(National Cancer Institute), Umberto Vitolo(Candiolo Cancer Institute), Luigi Rigacci(Azienda Ospedaliero-Universitaria Careggi), Cinzia Iotti(Azienda Sanitaria Unità Locale di Reggio Emilia)
Cited by 5
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
|Journal of Clinical Oncology|2001|628